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Abstract. Anal cancer is a rare type of digestive tract disease, 
which has had a crescent incidence in a number of regions. 
Carcinomas are most frequently found, with squamous cell 
carcinoma (SCC) comprising ~95% of all anal tumors. The 
major risk factor for development of this type of tumor is human 
papillomavirus (HPV) infection. However, previous studies 
have identified patients with anal cancer that are HPV‑/p16-and 
observed that they have a poorer outcome compared with 
HPV+/p16+ patients. This suggests that molecular profile may 
drive anal cancer progression. The aim of the present study was 
to evaluate the mutational status of two important oncogenes, 
KRAS and BRAF, in a series of anal cancer lesions. Resected 
tumors of the anal canal (n=43) were evaluated, nine of these 
were high-grade squamous intra-epithelial lesion cases (HSIL), 
11 were adenocarcinomas, and 23 SCCs. Direct sequencing of 
KRAS proto-oncogene, GTPase (KRAS; codons 12 and 13) 
and B-Raf proto-oncogene, serine/threonine kinase (BRAF; 
codon 600) was performed and associated with patient clini-
copathological and molecular features. There was a trend of 
poorer prognosis of adenocarcinoma compared with HSIL and 
SCC. Analysis indicated one SCC patient (2.3%) exhibited a 
KRAS p.G13D mutation, and one adenocarcinoma patient 
(2.3%) exhibited a BRAF p.V600E mutation. It was observed 
that, these mutations are rare in anal tumors, and certain patients 
may be at a disadvantage using targeted therapies based on 
KRAS and BRAF mutational status. As there is a low mutation 
percentage in SCCs, adenocarcinomas and HSIL, there may 
exist other underlying molecular alterations that result in anal 
cancer development, which require further elucidation.
Introduction
Anal cancer is a rare type of digestive tract disease, which has 
had an increasing incidence in a number of regions (1-3). It 
is estimated a total of >7,200 new cases were diagnosed in 
the United States in 2015, with ~1,000 anal cancer-associated 
mortalities (4). Tumors in this site are classified, according 
to World Health Organization (WHO), as intraepithelial 
neoplasias, carcinomas and carcinoid tumors (5). Carcinomas 
are most frequently identified, with squamous cell carcinoma 
(SCC) comprising~95% of all the anal tumors (6), and ~5% 
of the lesions are adenocarcinomas (7). The age-standard-
ized incidence is <1/100,000 people, and the mortality is 
0.2/100,000 (1). In men who practice anal receptive intercourse, 
the incidence of anal cancer increases up to 35/100,000 (5,8). 
This is predominantly due to increased risk of human papil-
lomavirus (HPV) infection (1), HPV16 is most frequently 
observed in anal SCC (9). HPV infection leads to intraepithe-
lial neoplasia that progresses from low-grade to high-grade 
dysplasia and, finally, to invasive cancer. The regression of 
high-grade dysplastic lesions is rare (5). HPV infection results 
in high expression of cyclin-dependent kinase inhibitor 2A 
(p16), and disrupts the association between retinoblastoma 
protein and the E2F family of transcription factors, ultimately 
leading to cellular proliferation (10). Recently, it was demon-
strated that a high frequency of women with cervical cancer 
also have infection of the anal canal by HPV16 (11). In addi-
tion to HPV infection, other known risk factors of anal cancer 
are immunodeficiency due to human immunodeficiency virus 
seropositivity, low cluster of differentiation 4 T cell count, 
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immunosuppression following solid organ transplantation, and 
tobacco smoking (1,5).
Previous studies have indicated that patients presenting 
with no HPV infection and no p16 expression (HPV-/p16-) 
have a poorer outcome than patients that are HPV+/p16+, and 
suggest an optimization in the therapy to the former (12,13), 
and that improved molecular characterization should be 
performed. A previous study demonstrated that patients with 
SCC of the anal canal and HPV were irresponsive to standard 
chemoradiotherapy treatment and frequently presented with 
TP53 mutations (13). Furthermore, an additional study using 
immunohistochemistry (IHC), fluorescence in situ hybridiza-
tion and next generation sequencing, observed alterations in 
molecular markers that may aid in the understanding of failure 
of certain therapeutic strategies, including overexpression of 
multidrug resistance-associated protein 1, DNA excision repair 
protein ERCC-1 and thymidylate synthetase, and suggest 
potential therapeutic targets, including the tyrosine kinase 
receptor, epidermal growth factor receptor (EGFR) (14). 
Molecular therapies targeting EGFR, such as cetuximab and 
panitumumab are currently used in colorectal cancer treat-
ment, and tumor genetic make-up, including mutational status 
of KRAS and BRAF may predict patient response (15).
The aim of the present study is to evaluate the mutational 
status of two important oncogenes, KRAS and BRAF in a 
series of SCC, adenocarcinomas and high-grade squamous 
intra-epithelial lesions (HSILs), and whether they are associ-
ated with patient's clinicopathological features, and HPV 
status.
Materials and methods
In the current study, resected tumors of the anal canal from 
43 patients were evaluated. The present study was approved by 
the ethics committee of Barretos Cancer Hospital (Barretos, 
Brazil) and informed consent was obtained from each 
patient. Histological review of the slides was performed by an 
expert pathologist (Dr Cristovam Scapulatempo-Neto), who 
confirmed the diagnosis and delimited the area of the slide 
containing the neoplastic lesion. Clinical data of the patients 
was obtained, and is summarized in Table I. HPV16 and HPV18 
status, and immunohistochemical analysis of β-globin, p16, 
antigen Ki67 (Ki67), minichromosome maintenance protein 
complex (MCM) and DNA topoisomerase 2-α (TOP2A) were 
retrieved from a previous study (16).
The histological slides (10 µm) were processed, and DNA 
was isolated from macrodissected tumor area of one unstained 
section as previously described (17). The slides were placed at 
80˚C for deparaffinization for 10 min and hydrated with xylene 
and graded ethanol (100, 70 and 50%). DNA was isolated using 
QIAamp DNA Micro kit (Qiagen GmbH, Hilden, Germany), 
following the manufacturer's protocols, and quantified using 
NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). The samples were diluted to a final concentration 
of 50 ng/µl and stored at ‑20˚C for further analysis.
The hotspots of KRAS (codons 12 and 13) and BRAF 
(codon 600) were amplified using PCR and sequenced, 
as previously described (17). Amplification of KRAS was 
performed in a final reaction volume of 15 µl containing 
1.5 µl buffer (Qiagen GmbH), 2 mM MgCl2 (Qiagen GmbH), 
100 mM dNTPs (Invitrogen; Thermo Fisher Scientific, Inc.), 
0.2 mM sense and 0.2 mM anti-sense primers (Sigma-Aldrich, 
St. Louis, MO, USA), 1 unit HotStarTaq DNA polymerase 
(Qiagen GmbH) and 1 µl DNA. The KRAS region was 
amplified using the following primers: Sense, 5'‑GTG TGA 
CAT GTT CTA ATA TAG TCA-3' and anti-sense, 5'-GAA TGG 
TCC TGC ACC AGTAA-3'. The BRAF amplification reaction 
was performed as described above, with 0.3 mM sense and 
anti-sense primers used. The region was amplified using the 
following primers: Sense, 5'-TCA TAA TGC TTG CTC TGA 
TAGGA-3' and anti-sense, 5'-GGC CAA AAA TTT AAT CAG 
TGGA-3'. The following cycling conditions were used: Initial 
denaturation at 96˚C for 15 min, followed by 40 cycles of dena-
turation at 96˚C for 45 sec, annealing at 55.5˚C for 45 sec, then 
extension at 72˚C for 10 min, all using a Veriti 96‑Well thermal 
cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.)
The PCR products were purified with EXO-SAP (GE 
Healthcare Life Sciences, Chalfont, UK), and sequenced using 
1 µl BigDye (Applied Biosystems; Thermo Fisher Scientific, 
Inc.), 1.5 µl sequencing buffer (Applied Biosystems; Thermo 
Fisher Scientific, Inc.) and 1 µl primer (Thermo Fisher Scientific, 
Inc.). The sequencing reaction, which consisted of 30 cycles of 
denaturation at 96˚C for 10 sec, annealing at 50˚C for 5 sec and 
extension at 60˚C for 4 min, was followed by post‑sequencing 
purification with EDTA, alcohol and sodium citrate. The prod-
ucts of PCR were eluted in Hi-Di formamide (Thermo Fisher 
Figure 1. Kaplan-Meier curves representing (A) overall survival and (B) disease-free survival of HSIL, adenocarcinoma and squamous cell carcinoma patients. 
HSIL, high-grade squamous intra-epithelial lesion.
  A   B
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Table I. Clinicopathological features of patients with anal lesions.
 Frequency (%)
 ----------------------------------------------------------------------------------------------------------------------------------------------
Parameter HSIL Adenocarcinoma SCC
Gender 
  Female 6 (20.7) 7 (24.1) 16 (55.2)
  Male 3 (21.4) 4 (28.6) 7 (50.0)
Ethnicity 
  Caucasian 8 (21.6) 8 (21.6) 21 (56.8)
  Non-caucasian 1 (16.7) 3 (50) 2 (33.3)
History of previous disease
  No 2 (11.1) 7 (38.9) 9 (50.0)
  Yes 7 (29.2) 3 (12.5) 14 (58.3)
  NA 0 1 (100) 0
History of tumor in the family
  No 6 (21.4) 6 (21.4) 16 (57.1)
  Yes 3 (21.4) 4 (28.6) 7 (50.0)
  NA 0 1 (100) 0
Tobacco consumption 
  No 1 (5.6) 7 (38.9) 10 (55.6)
  Yes 7 (33.3) 3 (14.3) 11 (52.4)
  NA 1 (25.0) 1 (25.0) 2 (50.0)
Surgery
  No 6 (26.1) 6 (26.1) 11 (47.8)
  Yes 3 (16.7) 5 (27.8) 10 (55.6)
  NA 0 0 2 (100)
Radiotherapy
  No 2 (40.0) 1 (20.0) 2 (40.0)
  Yes 7 (19.4) 10 (27.8) 19 (52.8)
  NA 0 0 2 (100)
Chemotherapy
  No 2 (25.0) 3 (37.5) 3 (37.5)
  Yes 7 (21.2) 8 (24.2) 18 (54.5)
  NA 0 0 2 (100)
Response to the treatment
  No response 4 (23.5) 6 (35.3) 7 (41.2)
  Complete response 1 (8.3) 2 (16.7) 9 (75.0)
  Progression 2 (22.2) 2 (22.2) 5 (55.6)
  NA 2 (40.0) 1 (20.0) 2 (40.0)
Recurrence
  No 7 (22.6) 6 (19.4) 18 (58.1)
  Yes 2 (16.7) 5 (41.7) 5 (41.7)
Status
  Death by cancer 3 (23.1) 4 (30.8) 6 (46.2)
  Death by other cause 0 2 (66.7) 1 (33.3)
  Alive, free of disease 6 (27.3) 3 (13.6) 13 (59.1)
  Alive, with the disease 0 2 (40.0) 3 (60.0)
Age (years)
  <48 3 (33.3) 1 (11.1) 5 (55.6)
  48-66 5 (20.0) 6 (24.0) 14 (56.0)
  >66 1 (11.1) 4 (44.4) 4 (44.4)
NA, not available.
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Scientific, Inc.) and incubated at 95˚C for 5 min and at ‑4˚C for at 
least 5 min. Direct sequencing was performed in a 3500 Genetic 
Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). 
The mutations were confirmed with two independent reactions.
Survival analysis was performed considering the three 
different histology types using Kaplan-Meier plots and log 
rank statistical analysis using R.
Results
Histological review of the slides demonstrated that, from the 
43 patients, 9 were diagnosed with HSIL, 11 patients were diag-
nosed with adenocarcinomas, and 23 with SCC. The mean age at 
diagnosis varied from 51 (HSIL) to 64 (adenocarcinoma) years. 
Overall survival (OS) and disease-free survival (DFS), based on 
the histologic type is presented in Fig. 1. There was a trend of 
poorer prognosis in adenocarcinoma compared with HSIL and 
SCC (P=0.176 and P=0.112 for OS and DFS, respectively).
Of the 43 patient samples examined, 1 (2.3%), exhibited 
a KRAS mutation, which was p.G13D (Fig. 2A and Table II). 
This case was a female SCC patient (age, 58) with previous 
gynecological or anal disease. The SCC was positive for 
β-globin and p16 using IHC, as well as 4+ Ki67 labeling. 
Notably, this patient also presented with HPV16 anal infection 
(Table II). Following surgery, radiotherapy and chemotherapy 
treatment, the patient exhibited complete response, and was 
free of disease at the last follow up of 140 months (Table II).
A BRAF mutation, p.V600E, was also observed in only 
1/43 patients (2.3%; Fig. 2B and Table II). This case was an 
adenocarcinoma of a male 70 year-old tobacco smoking patient. 
Similarly to the case described above, the patient also presented 
with HPV16 anal infection, and IHC indicated positivity for 
β-globin and p16 IHC labeling, as well as 4+ Ki67 labeling 
(Table II). In addition, the sample presented 3+ MCM and 
3+ TOP2A IHC labeling. The patient relapsed and succumbed 
to the condition 2 months following surgery (Table II).
Discussion
The present study aimed to evaluate the mutational status of 
KRAS and BRAF in tumors arising in the anal canal, and to 
associate these findings with clinicopathological data. To the 
best of our knowledge, the majority of the mutational screening 
of KRAS and BRAF in anal tumors focused on SCC samples 
due to the predominance of this histological type in anal tumors.
Although tumors located in the anal region may be 
anatomically close to colorectal tumors, they exhibit different 
histological patterns, distinct features, and therefore distinct 
etiologies (18). Previous studies have observed a high 
incidence of KRAS mutation in colorectal cancer (CRC) 
worldwide (19), and in Brazilian populations (17,20). Overall, 
among 8,234 Brazilian CRC cases analyzed, the KRAS muta-
tion frequency of 31.9%, with the majority of these samples 
exhibiting a p.G12D mutation (20). KRAS mutations gener-
ally arise in codons 12 or 13, and constitutively activate its 
pathway. The protein generated by the mutated gene is capable 
of transmitting the signal independently of tyrosine kinase 
receptor activation (21). Of the 43 patients analyzed, 1 patient 
with SCC was observed to have a KRAS mutation (2.3%). This 
low mutation rate is consistent with previous studies, which 
identified no KRAS mutation in SCC of the anal canal samples 
[n=36 samples (22), n=89 samples (23), n=53 samples (24) 
and n=66 samples (25)]. Additional studies observed a total 
of 1.6% (n=193 samples) (26), and 5% (n=84 samples) (27) of 
SCC to have a KRAS mutation. Furthermore, BRAF, another 
mitogen-activated protein kinase pathway gene, which was 
identified as mutated in ~50% of melanomas (28), presented 
a low mutation rate in the samples in the present study (2.3%). 
This gene was observed with a low percentage of mutation in 
anal tumors, varying from 0% (24,25,27) to 4.7% (26) consis-
tent with the findings of the current study. In addition, this 
gene was also found mutated in a low percentage of precursor 
lesions of colorectal cancer (17) and colorectal cancer (29). 
It is important to highlight that no mutation was observed in 
patients with HSIL, which suggest that these mutations may 
occur preferentially in tumors with an invasive phenotype.
The standard treatment of anal SCC in the majority of 
patients is chemotherapy and radiotherapy, with a response 
rate of up to 80% (30). Metastatic and refractory cases are 
rare, although, it has been demonstrated that cetuximab-based 
treatment results in disease progression of KRAS-mutated 
tumors, while those with wild type KRAS exhibited partial 
or minor remission (31). This data is consistent with further 
studies in colorectal cancer that demonstrated KRAS and 
BRAF mutational status predicted tumor response to targeted 
therapies (15). Thus, an understanding of KRAS and BRAF 
mutational status is key in personalized medicine.
Using the mutational rate of KRAS and BRAF, the present 
study evaluated the anatomical association between anal 
and rectal tumors, tumors arising in the anus have different 
KRAS mutation percentage of the rectal counterparts, thus, 
the molecular differences require elucidation. To the best of 
our knowledge, the current study is the first to evaluate the 
percentage of KRAS and BRAF mutations in adenocarcinomas 
and HSIL of the anal canal, in addition to SCC. Furthermore, 
to date, the present study is the first to describe these mutations 
in tumors of anal canal of the Brazilian population. In addition 
Figure 2. Electropherograms representing the mutations in (A) KRAS 
(p.G13D) and (B) BRAF (p.V600E).
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to the well-known risk factor of HPV infection that drives 
anal cancer tumorigenesis, there are patients who develop 
these tumors in the absence of this infection. The present 
study evaluated the mutation percentage of two well-known 
drivers of colorectal cancer (KRAS) and melanoma (BRAF) to 
further elucidate other risk factors in anal cancer development. 
In conclusion, a low percentage of mutation was identified in 
SCCs, adenocarcinomas and HSIL, however, these tumors may 
exhibit other molecular alterations that result in anal cancer 
development, which require elucidation in future studies.
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